Wednesday, June 10, 2026

pharma Β· Patency of the Ductus Arteriosus Β· Atopic Dermatitis Β· CNTB

S.L

S.L clinical programs β€” 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

SAN DIEGO, CA, EU HQ
Public company Type
CNTB Β· NYSE Ticker
Company details
Status
Public
HQ
SAN DIEGO, CA, EU
Programs
15
Drugs
11
Patents
179
Intelligence Β· Clinical Programs

S.L projects

15 ClinicalTrials.gov programs sponsored by S.L.

S.L has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Acetaminophen

    S.L

    Patency of the Ductus Arteriosus

    phase 3 small molecule completed

    1 trial
  2. CBP-201

    S.L

    Atopic Dermatitis

    phase 3 small molecule active

    2 trials
  3. CBP-201

    S.L

    Moderate to Severe Persistent Asthma

    phase 2 small molecule completed

    1 trial
  4. CBP-201

    S.L

    Chronic Rhinosinusitis With Nasal Polyps

    phase 2 small molecule terminated

    1 trial
  5. CBP-201

    S.L

    Moderate-to-severe Atopic Dermatitis

    phase 2 small molecule completed

    2 trials
  6. Double-Blind 0.2mg CBP-307

    S.L

    Moderate to Severe Ulcerative Colitis

    phase 2 small molecule completed

    1 trial
  7. Rademikibart in prefilled syringe

    S.L

    Asthma Acute

    phase 2 other active

    1 trial
  8. Rademikibart in prefilled syringe

    S.L

    COPD Acute Exacerbation

    phase 2 other active

    1 trial
  9. umbilical cord blood (hUCB) cells

    S.L

    Cerebral Palsy

    phase 2 mab completed

    1 trial
  10. CBP-174

    S.L

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial
  11. CBP-201-CN004

    S.L

    Healthy Adult Subjects

    phase 1 mab completed

    1 trial
  12. CBP-307

    S.L

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial
  13. CBP-307

    S.L

    Autoimmune Diseases

    phase 1 small molecule completed

    2 trials
  14. Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

    S.L

    STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder

    phase 1 small molecule active

    1 trial
  15. vitamin D3

    S.L

    X-linked Adrenoleukodystrophy

    phase 1 other completed

    1 trial

Frequently asked questions

How many clinical projects does S.L have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.